Neurocrine Biosciences (NBIX) Amortization of Deferred Charges (2017 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Amortization of Deferred Charges of $900000.0 for Q2 2026, down 87.32% year-over-year from $7.1 million in Q2 2025, and down 66.67% on a QoQ basis from $2.7 million in Q1 2026.
Neurocrine Biosciences (NBIX) Amortization of Deferred Charges (2017 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Amortization of Deferred Charges for 10 years, with the latest figure at $900000.0 in Q2 2026.
- Amortization of Deferred Charges for Q2 2026 came in at $900000.0, down 87.32% year-over-year; the trailing twelve-month figure through Jun 2026 was $17.3 million (up 17.69% YoY), and the FY2023 annual result was $700000.0, down 41.67% from the prior year.
- Amortization of Deferred Charges eased to $900000.0 in Q2 2026, from $2.7 million in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $7.2 million in Q1 2025 and troughed at $100000.0 in Q4 2023.
- A 5-year average of $1.9 million and a median of $350000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- The widest annual swing landed in 2025, when Amortization of Deferred Charges soared 2100.0%; it then sank 87.32% in 2026.
- A 5-year view of Amortization of Deferred Charges shows it stood at $200000.0 in 2022, then plunged by 50.0% to $100000.0 in 2023, then surged by 200.0% to $300000.0 in 2024, then soared by 2100.0% to $6.6 million in 2025, then tumbled by 86.36% to $900000.0 in 2026.
- Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $900000.0 in Q2 2026, $2.7 million in Q1 2026, and $6.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 900,000.00 |
| Jun 30, 2026 | 900,000.00 |
| Mar 31, 2026 | 2.70 Mn |
| Mar 31, 2026 | 2.70 Mn |
| Sep 30, 2025 | 6.60 Mn |
| Sep 30, 2025 | 6.60 Mn |
| Jun 30, 2025 | 7.10 Mn |
| Jun 30, 2025 | 7.10 Mn |
| Mar 31, 2025 | 7.20 Mn |
| Mar 31, 2025 | 7.20 Mn |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 200,000.00 |
| Mar 31, 2023 | 200,000.00 |
| Mar 31, 2023 | 200,000.00 |